Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma

Leukemia Research Reports

Michael J. Robertson¹  Suheil Albert Atallah-Yunes² 

[1] Corresponding author at: Division of Hematology and Medical Oncology – Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, 535 Barnhill Drive, Indianapolis, IN 46202, USA.;Division of Hematology and Medical Oncology – Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA;

关键词: Lymphoma;    Immunotherapy;    Monoclonal antibodies;    Antibody drug conjugates;    Bispecific antibodies;   

DOI  :  

来源: DOAJ

【 摘 要 】

The improvement in outcomes seen with the introduction of rituximab, a CD20 monoclonal antibody in combination with chemotherapy or as a single agent in the treatment of indolent non-Hodgkin lymphomas has paved the way for development of various forms of monoclonal antibodies that act in different ways against non-Hodgkin lymphoma tumor cells. These could directly target a single surface antigen resulting in various ways of tumor cells toxicity and killing. Other forms of monoclonal antibodies include antibody-drug conjugates and bispecific antibodies. The role of therapeutic monoclonal antibodies in the treatment of lymphoma will be reviewed, highlighting their mode of action, clinical efficacy, and side effects.

【 授权许可】

Unknown